Efficacy and safety of remimazolam besylate in the obese patients during colonoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049951

Enrollment

Unknown

Registered

2021-08-14

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none

Interventions

Propofol group:propofol for sedation

Remimazolam group:remimazolam for sedation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. ASA I-III; 2. aged 18-64 years old; 3. Body mass index (BMI) >=30 kg/m2.

Exclusion criteria

Exclusion criteria: 1. II or III degree atrioventricular block; 2. Severe heart, lung, liver or kidney dysfunction; 3. Suffering from central nervous system disease or neuropsychiatric disease; 4. Use of sedative-hypnotics or analgesics for >3 months; 5. Hypersensitivity to remazolam or propofol. 6. Refused to sign the informed consent.

Design outcomes

Primary

Measure	Time frame
oxygen- desaturation episodes;	—

Secondary

Measure	Time frame
apnea episodes;airway interventions;bradycardia;body movement;Patient data fluctuations;time to consciousness loss;awakening time;discharge time;total colonoscopy time;	—

Countries

China

Contacts

Public ContactXing Na

The First Affiliated Hospital of Zhengzhou University

16427485@qq.com+86 13949095172

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026